Alfonso Salgado-Cortes

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Effectiveness of radiofrequency therapy combined with pelvic floor muscle training in breast cancer survivors with genitourinary syndrome of menopause: a study protocol.

Effectiveness of radiofrequency therapy combined with pelvic floor muscle training in breast cancer survivors with genitourinary syndrome of menopause: a study protocol.

Journal: European journal of obstetrics, gynecology, and reproductive biology

Published: December 20, 2025

A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 19, 2025

Assessing platinum response in first-line advanced ovarian cancer: clinical implications and future directions.

Assessing platinum response in first-line advanced ovarian cancer: clinical implications and future directions.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 18, 2025

Corrigendum to "HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study" [Gynecologic Oncology 194 (2025) 33-40].

Corrigendum to "HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study" [Gynecologic Oncology 194 (2025) 33-40].

Journal: Gynecologic oncology

Published: November 09, 2025

MDM4 amplification as a potential predictor of risk of recurrence in early-stage low-grade endometrial carcinoma.

MDM4 amplification as a potential predictor of risk of recurrence in early-stage low-grade endometrial carcinoma.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 30, 2025

A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer.

A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer.

Journal: Cancer research communications

Published: July 25, 2025

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 23, 2025

Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification.

Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification.

Journal: The Journal of pathology

Published: June 24, 2025

HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.

HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.

Journal: Gynecologic oncology

Published: November 06, 2024

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.

Journal: Nature medicine

Published: November 05, 2024

Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study.

Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study.

Journal: The oncologist

Published: March 11, 2024

Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.

Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.

Journal: Cancer

Published: January 09, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026